Spread the love

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Molecular therapy for Metabolic disorders: Tumor suppressor ING1b decreases insulin sensitivity, mucosal immunity and increases endotoxaemia via down regulation of Interleukin-22, 28/October/2014, 22.32, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Undisclosed information: An insight into how ING1b decreases insulin sensitivity, mucosal immunity and increases endotoxaemia.

Significance: This study suggests, for the first time, that  ING1b, by decreasing the expression of IL-22, it may decrease insulin sensitivity, gut immunity; and increase endotoxaemiaTogether, this study suggests that pharmacological formulations encompassing ING1b inhibitors may be used to treat metabolic disorders, including T2DM and cardiac diseases.

Spread the love